These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

398 related articles for article (PubMed ID: 22086061)

  • 1. Tumor-specific retargeting of an oncogenic transcription factor chimera results in dysregulation of chromatin and transcription.
    Patel M; Simon JM; Iglesia MD; Wu SB; McFadden AW; Lieb JD; Davis IJ
    Genome Res; 2012 Feb; 22(2):259-70. PubMed ID: 22086061
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EWS/FLI mediated reprogramming of 3D chromatin promotes an altered transcriptional state in Ewing sarcoma.
    Showpnil IA; Selich-Anderson J; Taslim C; Boone MA; Crow JC; Theisen ER; Lessnick SL
    Nucleic Acids Res; 2022 Sep; 50(17):9814-9837. PubMed ID: 36124657
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EWS/FLI and its downstream target NR0B1 interact directly to modulate transcription and oncogenesis in Ewing's sarcoma.
    Kinsey M; Smith R; Iyer AK; McCabe ER; Lessnick SL
    Cancer Res; 2009 Dec; 69(23):9047-55. PubMed ID: 19920188
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of two types of GGAA-microsatellites and their roles in EWS/FLI binding and gene regulation in Ewing sarcoma.
    Johnson KM; Taslim C; Saund RS; Lessnick SL
    PLoS One; 2017; 12(11):e0186275. PubMed ID: 29091716
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional Genomic Screening Reveals Splicing of the EWS-FLI1 Fusion Transcript as a Vulnerability in Ewing Sarcoma.
    Grohar PJ; Kim S; Rangel Rivera GO; Sen N; Haddock S; Harlow ML; Maloney NK; Zhu J; O'Neill M; Jones TL; Huppi K; Grandin M; Gehlhaus K; Klumpp-Thomas CA; Buehler E; Helman LJ; Martin SE; Caplen NJ
    Cell Rep; 2016 Jan; 14(3):598-610. PubMed ID: 26776507
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Suppression of FOXO1 is responsible for a growth regulatory repressive transcriptional sub-signature of EWS-FLI1 in Ewing sarcoma.
    Niedan S; Kauer M; Aryee DN; Kofler R; Schwentner R; Meier A; Pötschger U; Kontny U; Kovar H
    Oncogene; 2014 Jul; 33(30):3927-38. PubMed ID: 23995784
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EWS-FLI1 regulates a transcriptional program in cooperation with Foxq1 in mouse Ewing sarcoma.
    Shimizu R; Tanaka M; Tsutsumi S; Aburatani H; Yamazaki Y; Homme M; Kitagawa Y; Nakamura T
    Cancer Sci; 2018 Sep; 109(9):2907-2918. PubMed ID: 29945296
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-throughput RNAi screen in Ewing sarcoma cells identifies leucine rich repeats and WD repeat domain containing 1 (LRWD1) as a regulator of EWS-FLI1 driven cell viability.
    He T; Surdez D; Rantala JK; Haapa-Paananen S; Ban J; Kauer M; Tomazou E; Fey V; Alonso J; Kovar H; Delattre O; Iljin K
    Gene; 2017 Jan; 596():137-146. PubMed ID: 27760381
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epigenome editing of microsatellite repeats defines tumor-specific enhancer functions and dependencies.
    Boulay G; Volorio A; Iyer S; Broye LC; Stamenkovic I; Riggi N; Rivera MN
    Genes Dev; 2018 Aug; 32(15-16):1008-1019. PubMed ID: 30042132
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanism and relevance of EWS/FLI-mediated transcriptional repression in Ewing sarcoma.
    Sankar S; Bell R; Stephens B; Zhuo R; Sharma S; Bearss DJ; Lessnick SL
    Oncogene; 2013 Oct; 32(42):5089-100. PubMed ID: 23178492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mapping the Structure-Function Relationships of Disordered Oncogenic Transcription Factors Using Transcriptomic Analysis.
    Showpnil IA; Miller KR; Taslim C; Pishas KI; Lessnick SL; Theisen ER
    J Vis Exp; 2020 Jun; (160):. PubMed ID: 32658189
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted long-read sequencing of the Ewing sarcoma 6p25.1 susceptibility locus identifies germline-somatic interactions with EWSR1-FLI1 binding.
    Lee OW; Rodrigues C; Lin SH; Luo W; Jones K; Brown DW; Zhou W; Karlins E; Khan SM; Baulande S; Raynal V; Surdez D; Reynaud S; Rubio RA; Zaidi S; Grossetête S; Ballet S; Lapouble E; Laurence V; Pierron G; Gaspar N; Corradini N; Marec-Bérard P; Rothman N; Dagnall CL; Burdett L; Manning M; Wyatt K; Yeager M; Chari R; Leisenring WM; Kulozik AE; Kriebel J; Meitinger T; Strauch K; Kirchner T; Dirksen U; Mirabello L; Tucker MA; Tirode F; Armstrong GT; Bhatia S; Robison LL; Yasui Y; Romero-Pérez L; Hartmann W; Metzler M; Diver WR; Lori A; Freedman ND; Hoover RN; Morton LM; Chanock SJ; Grünewald TGP; Delattre O; Machiela MJ
    Am J Hum Genet; 2023 Mar; 110(3):427-441. PubMed ID: 36787739
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PI3K/AKT signaling modulates transcriptional expression of EWS/FLI1 through specificity protein 1.
    Giorgi C; Boro A; Rechfeld F; Lopez-Garcia LA; Gierisch ME; Schäfer BW; Niggli FK
    Oncotarget; 2015 Oct; 6(30):28895-910. PubMed ID: 26336820
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FOXM1 is an oncogenic mediator in Ewing Sarcoma.
    Christensen L; Joo J; Lee S; Wai D; Triche TJ; May WA
    PLoS One; 2013; 8(1):e54556. PubMed ID: 23365673
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EWS::FLI1 and HOXD13 Control Tumor Cell Plasticity in Ewing Sarcoma.
    Apfelbaum AA; Wu F; Hawkins AG; Magnuson B; Jiménez JA; Taylor SD; Wrenn ED; Waltner O; Pfaltzgraff ER; Song JY; Hall C; Wellik DM; Ljungman M; Furlan SN; Ryan RJH; Sarthy JF; Lawlor ER
    Clin Cancer Res; 2022 Oct; 28(20):4466-4478. PubMed ID: 35653119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma.
    Hensel T; Giorgi C; Schmidt O; Calzada-Wack J; Neff F; Buch T; Niggli FK; Schäfer BW; Burdach S; Richter GH
    Oncotarget; 2016 Jan; 7(2):1451-63. PubMed ID: 26623725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EWS-FLI1 and Menin Converge to Regulate ATF4 Activity in Ewing Sarcoma.
    Jiménez JA; Apfelbaum AA; Hawkins AG; Svoboda LK; Kumar A; Ruiz RO; Garcia AX; Haarer E; Nwosu ZC; Bradin J; Purohit T; Chen D; Cierpicki T; Grembecka J; Lyssiotis CA; Lawlor ER
    Mol Cancer Res; 2021 Jul; 19(7):1182-1195. PubMed ID: 33741715
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SLFN11 Is a Transcriptional Target of EWS-FLI1 and a Determinant of Drug Response in Ewing Sarcoma.
    Tang SW; Bilke S; Cao L; Murai J; Sousa FG; Yamade M; Rajapakse V; Varma S; Helman LJ; Khan J; Meltzer PS; Pommier Y
    Clin Cancer Res; 2015 Sep; 21(18):4184-93. PubMed ID: 25779942
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systems biology of Ewing sarcoma: a network model of EWS-FLI1 effect on proliferation and apoptosis.
    Stoll G; Surdez D; Tirode F; Laud K; Barillot E; Zinovyev A; Delattre O
    Nucleic Acids Res; 2013 Oct; 41(19):8853-71. PubMed ID: 23935076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proteasomal Degradation of the EWS-FLI1 Fusion Protein Is Regulated by a Single Lysine Residue.
    Gierisch ME; Pfistner F; Lopez-Garcia LA; Harder L; Schäfer BW; Niggli FK
    J Biol Chem; 2016 Dec; 291(52):26922-26933. PubMed ID: 27875302
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.